aka Coronavirus in developing tests for its presence, companies most likely to develop a vaccine to treat or prevent it,
also companies involved in anti-viral disinfectants for it. Thanks
This is a discussion topic or guest posting submitted by a Stock Gumshoe reader. The content has not been edited or reviewed by Stock Gumshoe, and any opinions expressed are those of the author alone.
Just some ideas:
“CODX”, maker of diagnostic kits for Covid-19 could go vertical once approved by FDA/CDC. The stock has already jumped 400% on news that their patented test kits offer results in 45-min, as opposed to 48-hours to send samples for testing at various state labs. They also advertise to be more accurate than the CDC tests, which have already given some “false-positives”.
“TOMZ”, is also under the radar, maker of sterilization machines, already approved/adopted by China. Could be in high demand if the virus spreads as rapidly in the U.S.
There is a slew of vaccine makers jumping on the bandwagon to develop a successful vaccine, but to the victor will go the spoils of that race. Even Israel has recently promised they will have a valid vaccine in “weeks”, but most virologist view that as a small miracle since animal testing, human testing Phase I/II/III would require months per phase before approval for mass production.
Also, checkout Ligand (LGND). The stock just started spiking on Friday’s news that company CEO made a statement that it is helping find a cure for the coronovirus. Can someone with an insight on the company’s products make comment on efficacy of the company to produce the vaccine for the virus? Is this stock good to own?
LGND is high priced and has been dropping
Thanks I picked up CODX early only wished I would have bet the farm on it. Thanks for the reply
Here is a summary of vaccines and medications for symptoms companies associated:
Clinical trials:
Drug/Treatment: Remdesivir
Drug/Treatment: Lopinavir /Ritonavir
Drug/Treatment: pirfenidone
Drug/Treatment: Arbidol or chloroquine phosphate
Drug/Treatment: Chloroquine
Drug/Treatment: Hydroxychloroquine
Vaccine: mRNA-1273 – Seattle, Washington
Vaccine: ChAdOx1 MERS – Saudi Arabia and The UK
https://clinicaltrials.gov/ct2/results?cond=Coronavirus&Search=Apply&recrs=b&recrs=a&recrs=f&recrs=d&recrs=m&age_v=&gndr=&type=Intr&rslt=Without
https://www.clinicaltrialsarena.com/analysis/coronavirus-mers-cov-drugs/
https://www.nih.gov/news-events/news-releases/nih-clinical-trial-investigational-vaccine-covid-19-begins
Novavax’s MERS coronavirus vaccine candidate
Inovio Pharma’s INO-4700
The investigational DNA immunotherapy, INO-4700 (GLS-5300) is being
developed by Inovio in partnership with GeneOne Life Science. It is
delivered as vaccine intramuscularly, using the Cellectra® delivery device.
INO-4800 by Inovio Pharmaceuticals and Beijing Advaccine Biotechnology
mRNA-1273 vaccine by Moderna and Vaccine Research Center
Vaccine by Medicago
Altimmune’s intranasal coronavirus vaccine
Avian Coronavirus Infectious Bronchitis Virus (IBV) vaccine by MIGAL Research Institute
Recombinant subunit vaccine by Clover Biopharmaceuticals
Vaxart’s coronavirus vaccine
Linear DNA Vaccine by Applied DNA Sciences and Takis Biotech
To be looked at:
AT-100 by Airway Therapeutics
TZLS-501 by Tiziana Life Sciences
OYA1 by OyaGen
BPI-002 by BeyondSpring
NP-120 (Ifenprodil) by Algernon Pharmaceuticals
APN01 by University of British Columbia and APEIRON Biologics
Avian Coronavirus Infectious Bronchitis Virus (IBV) vaccine by MIGAL Research Institute
TNX-1800 by Tonix Pharmaceuticals
Brilacidin by Innovation Pharmaceuticals
TJM2 by I-Mab Biopharma
CytoDyn-leronlimab
Favilavir, the first approved coronavirus drug in China
Thanks, helpful summary.
Time to revisit this go getter for use of Brilacidin against COVID-19
ZippyD — wanted to point out that there is a lot of promise with ” Brilacidin by Innovation Pharmaceuticals “, they are starting to make big announcements. (IPIX)
Preprint article details research conducted at George Mason’s Regional Biocontainment Laboratory:
Brilacidin shown in vitro to potently inhibit SARS-CoV-2, the novel coronavirus causing COVID-19.
In a human lung cell line infected by SARS-CoV-2, Brilacidin achieved a high Selectivity Index of 426.
The primary mechanism of action of Brilacidin appears to disrupt viral integrity and block viral entry.
Brilacidin and FDA-approved remdesivir exhibit excellent synergistic activity in vitro against SARS-CoV-2.
The preprint article is being submitted for peer-review publication
WAKEFIELD, Mass. and FAIRFAX, Va., Oct. 30, 2020 (GLOBE NEWSWIRE) — Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, and George Mason University’s (Mason’s) National Center for Biodefense and Infectious Diseases (NCBID), today jointly announce completion of extensive laboratory testing supporting anti-SARS-CoV-2 activity of Brilacidin, a defensin-mimetic drug candidate, which is being developed as a potential COVID-19 treatment.
Research findings are being submitted for peer-review publication. A preprint, available for download at the link below, is in the process of being posted to bioRxiv.org.
“Preprint: Brilacidin, a COVID-19 Drug Candidate, Exhibits Potent In Vitro Antiviral Activity Against SARS-CoV-2”
http://www.ipharminc.com/new-blog/2020/10/30/preprint-brilacidin-a-covid-19-drug-candidate-exhibits-potent-in-vitro-antiviral-activity-against-sars-cov-2
“We thank the scientists who have conducted an impressive amount of antiviral research on Brilacidin, which strongly supports its treatment potential in the fight against COVID-19,” commented Leo Ehrlich, Chief Executive Officer at Innovation Pharmaceuticals. “It is timely to have Brilacidin anchored in such sound science, as we anticipate commencing soon a clinical trial of Brilacidin for treatment of COVID-19. We look forward to continuing our antiviral research collaborations, while Brilacidin advances into clinical testing against COVID-19, where we believe Brilacidin can have a beneficial patient impact.”
Travis — you need to add IPIX to your Teaser Tracker, if not already there.
Brilacidin is about to be unleashed onto the COVID killer scene and you should make your audience aware.
https://apnews.com/press-release/globe-newswire/business-technology-virus-outbreak-pandemics-public-health-2cd30f2c5857fdb8137571865841b78b